Total trials
27
Active
9
Phase 3
0
Total enrollment
812
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide | — | — | — | — | — | 7 | |
| Fludarabine | — | — | — | — | — | 5 | |
| tacrolimus | — | — | — | — | — | 5 | |
| Rituximab | — | — | — | — | — | 4 | |
| methotrexate | — | — | — | — | — | 3 | |
| Rabbit ATG | — | — | — | — | — | 1 | |
| Sargramostim | — | — | — | — | — | 1 | |
| Blinatumomab | — | — | — | — | — | 1 | |
| Mycofenolate mofetil | — | — | — | — | — | 1 | |
| Belumosudil | — | — | — | — | — | 1 | |
| Axatilimab | — | — | — | — | — | 2 | |
| Decitabine | — | — | — | — | 2 | ||
| Venetoclax | — | — | — | — | 2 |
Next readouts
- 2026-08-31
- 2026-09-18
- 2026-11-01
- 2026-12-31
- 2027-06-30
- 2027-08-31
- 2028-12-31
- 2029-08-01
Top conditions
- Myelodysplastic Syndromes5
- Leukemia4
- Lymphoma4
- Multiple Myeloma4
- Acute Myeloid Leukemia3
- Myelodysplastic Syndrome3
- Myeloproliferative Disorders2
- Multiple Myeloma and Plasma Cell Neoplasm2
Frequently asked questions about Northside Hospital, Inc.
- How many clinical trials does Northside Hospital, Inc. have on ClinicalTrials.gov?
- Northside Hospital, Inc. is listed as the lead sponsor on 27 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Northside Hospital, Inc.'s trials are in Phase 3?
- 0 of Northside Hospital, Inc.'s trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does Northside Hospital, Inc. focus on?
- Northside Hospital, Inc.'s most-studied conditions on ClinicalTrials.gov are Myelodysplastic Syndromes, Leukemia, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia.
- When are Northside Hospital, Inc.'s next clinical trial readouts?
- Northside Hospital, Inc. has 8 upcoming primary-completion readouts tracked here; the soonest is “CAR T-cell Therapy in Patients With Renal Dysfunction”, expected around 2026-08-31.